Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, which are activators of nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) and are useful to treat diseases caused by oxidative stress, such as neurodegenerative diseases or inflammation. Also provided are methods for their use and production.

Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use as Nrf2 activators and for their production.

Abstract: The present disclosure provides compounds of Formula (I), and salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be useful for inhibiting kinases, e.g., glycogen synthase kinase 3 (GSK3). The provided compounds may be able to selectively inhibit GSK3a, as compared to GSK3P and/or other kinases. The present disclosure further provides pharmaceutical compositions, kits, and methods of use, each of which involve the compounds. The compounds, pharmaceutical compositions, and kits may be useful for treating diseases associated with aberrant activity of GSK3a (e.g., Fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood seizure, intellectual disability, diabetes, acute myeloid leukemia (AML), autism, and psychiatric disorder).

Abstract: Provided are compounds of Formula A or I, or pharmaceutically acceptable salts thereof, and methods for their use and production.

Abstract: The present disclosure provides compounds of Formula (I), and salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be useful for inhibiting kinases, e.g., glycogen synthase kinase 3 (GSK3). The provided compounds may be able to selectively inhibit GSK3a, as compared to GSK3P and/or other kinases. The present disclosure further provides pharmaceutical compositions, kits, and methods of use, each of which involve the compounds. The compounds, pharmaceutical compositions, and kits may be useful for treating diseases associated with aberrant activity of GSK3a (e.g., Fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood seizure, intellectual disability, diabetes, acute myeloid leukemia (AML), autism, and psychiatric disorder).

Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, which are activators of nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) and are useful to treat diseases caused by oxidative stress, such as neurodegenerative diseases or inflammation. Also provided are methods for their use and production.

Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.

Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.

Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use as Nrf2 activators and for their production.

Abstract: A sample testing apparatus is disclosed for use in optical transmission analysis of fluid samples such as oils or engine oils. The apparatus comprises a transmission cell comprising first and second fixed walls (1,2) and a movable window (3) that is moved with respect to the first and second walls in and out of a test region (6). When the movable window (3) is moved into the test region (6) an optical path through a fluid sample in the cell is defined, the optical path through the sample comprising a portion extending through the or each gap (L1,L2) between a one of the first and second fixed walls (1,2) and the at least a portion of the first movable window (3). Also disclosed are methods of using the sample testing apparatus and methods of performing a measurement for use in optical transmission analysis of a fluid sample.

Abstract: The present disclosure provides compounds of Formula (I), and salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be useful for inhibiting kinases, e.g., glycogen synthase kinase 3 (GSK3). The provided compounds may be able to selectively inhibit GSK3a, as compared to GSK3P and/or other kinases. The present disclosure further provides pharmaceutical compositions, kits, and methods of use, each of which involve the compounds. The compounds, pharmaceutical compositions, and kits may be useful for treating diseases associated with aberrant activity of GSK3a (e.g., Fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood seizure, intellectual disability, diabetes, acute myeloid leukemia (AML), autism, and psychiatric disorder).

Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, which are activators of nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) and are useful to treat diseases caused by oxidative stress, such as neurodegenerative diseases or inflammation. Also provided are methods for their use and production.

Abstract: Provided are tetrahydroisoquinoline derivatives as Nrf2 activators.

Abstract: A sample testing apparatus is disclosed for use in optical transmission analysis of fluid samples such as oils or engine oils. The apparatus comprises a transmission cell comprising first and second fixed walls (1,2) and a movable window (3) that is moved with respect to the first and second walls in and out of a test region (6). When the movable window (3) is moved into the test region (6) an optical path through a fluid sample in the cell is defined, the optical path through the sample comprising a portion extending through the or each gap (L1,L2) between a one of the first and second fixed walls (1,2) and the at least a portion of the first movable window (3). Also disclosed are methods of using the sample testing apparatus and methods of performing a measurement for use in optical transmission analysis of a fluid sample.

Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Abstract: A method and apparatus for scheduling are disclosed. The apparatus applies tests to microscope slides, where the slides are loaded in trays. Each tray is treated as a batch, and batches may be interleaved to reduce the total running time of testing all slides in up to three batches. The batches of slides have protocols that define the application of reagents such as primary antibodies. The protocols define open times, where no common resources are used, and use times, where common resources are used. The scheduler operates to ensure that the use times between batches does not overlap, without leaving the next step in the protocol for an excessive period of time.

Abstract: The present disclosure relates to a method for measuring the maturity or cell wall thickening of a sample of cellulosic fiber. The method at least includes exposing the sample of fiber to polarized light, capturing one or more images of the sample through crossed polar lenses and a compensator plate so that the image(s) include interference colors from the sample; and conducting computer analysis on the captured image(s) to determine the maturity or degree of cell wall thickening of the cellulosic fiber by comparing the image(s) to reference color interference data.

Abstract: The present invention relates to a method of enhancing a pro-inflammatory immune response through the administration of the DEAD-box protein DDX3, as encoded by SEQ ID NO:1. The invention further extends to a method of suppressing an aberrant immune response, such at that associated with autoimmune conditions, through inhibition of DDX3. The invention also extends to a method of suppressing a pro-inflammatory immune response through the administration of the vaccinia virus protein K7. The invention further extends to the provision of an attenuated poxvirus wherein the K7R gene which encodes for the K7 protein is deleted or rendered non-functional. Pharmaceutical compositions comprising DDX3 inhibitory compounds, such as K7, are also provided.

Abstract: The present invention relates to a method for measuring the maturity or cell wall thickening of a sample of cellulosic fibre. The method including the steps of: a) exposing the sample of fibre to polarized light; b) capturing one or more images of the sample through crossed polar lenses and a compensator plate so that the image(s) include interference colours from the sample; and c) conducting computer analysis on the image(s) captured in step b) to determine the maturity or degree of cell wall thickening of the cellulosic fibre by comparing the image(s) to reference colour interference data. The present invention also relates to an apparatus for carrying out the method. The apparatus including an optical light path for exposing the sample of fibre to polarized light, an image capturing means, and a computer for conducting image analysis to determine fibre maturity or the degree of cell wall thickening.

Abstract: A method and apparatus for scheduling are disclosed. The apparatus applies tests to microscope slides, where the slides are loaded in trays. Each tray is treated as a batch, and batches may be interleaved to reduce the total running time of testing all slides in up to three batches. The batches of slides have protocols that define the application of reagents such as primary antibodies. The protocols define open times, where no common resources are used, and use times, where common resources are used. The scheduler operates to ensure that the use times between batches does not overlap, without leaving the next step in the protocol for an excessive period of time.